Medicine
Sucraid 8500 IU/mL oral solution
Sucraid 8500 IU/mL oral solution is a prescription medicine containing Sacrosidase for oral use, marketed by QOL Medical, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store under refrigeration at 2°C to 8°C (36°F to 46°F). NDC# 67871-111-07 (150…
Key facts
- Active ingredient (INN)
- Sacrosidase
- Brand
- Sucraid
- Strength
- 8500 IU/mL
- Dosage form
- Oral solution
- Route
- Oral
- Packs
- 2 bottles, 6 boxes
- Marketing authorisation holder
- QOL Medical
- Manufacturer
- QOL Medical
- Origin register
- US FDA, United States
- Storage
- Store under refrigeration at 2°C to 8°C (36°F to 46°F). NDC# 67871-111-07 (150 x 2 mL single-use containers) Store under refrigeration, 2°C to 8°C (36°F to 46°F). Single-use container can be removed from refrigeration and stored at 15°C to 25°C (59°F to 77°F) for up to 3 days (72 hours).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A16AB06 Sacrosidase
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 9 April 1998
- Identifiers
- RxCUI 213337, 312872DailyMed set ID d613bb7f-c3f4-462e-81a2-da2347cc4b6bNDC 67871-111Application BLA020772
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 bottle in 1 carton / 118 mL in 1 bottle | 67871-111-04 | QOL Medical | 9 April 1998 |
| 6 box in 1 carton / 25 pouch in 1 box / 5 vial, single-use in 1 pouch / 2 mL in 1 vial, single-use | 67871-111-07 | QOL Medical | 25 May 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 9 April 1998 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Sacrosidase is a sucrose-specific enzyme indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older. It is available as oral solution. MedsAcross supplies Sacrosidase for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SacrosidaseFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Sucraid prescribing information (QOL Medical) · U.S. National Library of Medicine, DailyMed
Need Sucraid 8500 IU/mL oral solution for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.